FDA Inspection 1093449 — Carter BloodCare

Carter BloodCare — FEI 3002603147

The FDA completed an inspection of Carter BloodCare on April 12, 2019 in Bedford, TX. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Biologics.

Inspection Details

Classification
No Action Indicated (NAI) (NAI)
End Date
April 12, 2019
Fiscal Year
2019
Product Type
Biologics
Project Area
Blood and Blood Products
Location
Bedford, TX (United States)